Heart Failure 2018 & World Congress on Acute Heart Failure

26 - 29 May 2018, Vienna - Austria

Session Details

Poster Session 2: Chronic Heart Failure – Pathophysiology and Mechanisms
Sun 27 May 08:30 - 18:00 Other Poster Session Poster Area -

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30P931Cardiopulmonary exercise testing in pulmonary hypertension associated with congenital heart disease vs. other forms of pulmonary hypertension: physiological insights 
08:30P932The occurence of Heart failure result in low weight at birth in woman with congenital heart diseaseSonila BELE (Tirana, Albania)
08:30P933Relationship between serotonergic-modulating psycoactive treatments and 24-hour Cheyne-Stokes respiration occurrence in systolic heart failure.Gianluca MIRIZZI (Pisa, Italy)
08:30P934The association between markers of fibrosis and myocardial dyssynchrony in patients with CHFAlexandr BILCHENKO (Kharkov, Ukraine)
08:30P935Circulating biomarkers of inflammation and left ventricular hypertrophy in patients with heart failure with preserved ejection fractionAlexandr BILCHENKO (Kharkov, Ukraine)
08:30P936Radiation induced valve disease and cardiotoxicity induced heart failure is frequentJutta BERGLER-KLEIN (Vienna, Austria)
08:30P937Dual cardioprotection improves right and left ventricular systolic function in patients receiving cardiotoxic chemotherapyAna FERREIRA (London, United Kingdom)
08:30P938Cancer therapeutic related cardiac dysfunction among active breast cancer patients: A Cardio-Oncology registryMichal LAUFER-PERL (Tel Aviv, Israel)
08:30P939Mesalazine-induced cardiotoxicity: a retrospective study initial resultsCristina GOENA VIVES (San Sebastian, Spain)
08:30P940Haemodynamic changes associated with Cheyne-Stokes respiration in patients with heart failure: an echocardiographic studyAlberto GIANNONI (S. Croce S/Arno, Italy)
08:30P941Combined post- and pre-capillary pulmonary hypertension in heart transplant candidates with ischemic versus nonischemic etiologyZubeyde BAYRAM (Istanbul, Turkey)
08:30P942Effect of ischemic versus nonischemic cardiomyopathy on invasive hemodynamic findings in heart transplant candidatesZubeyde BAYRAM (Istanbul, Turkey)
08:30P943Experience using sacubitril/valsartan in real life: tolerability and clinical evolution in a long termRafael BRAVO MARQUES (Marbella, Spain)
08:30P944What is the significance of right ventricular dysfunction in patients with preserve, mid-range and depressed LVEF?Susana DEL PRADO DIAZ (Madrid, Spain)
08:30P945Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertensionMatthias SCHNEIDER (Vienna, Austria)
08:30P946Metabolic syndrome phenotypes have different effects on the diastolic function of the left ventricle and arterial ageingAiste Monika JAKSTAITE (Vilnius, Lithuania)
08:30P947Diastolic dysfunction of the right ventricle as an early diagnostic marker of heart failureVenera KIRILLOVA (Ekaterinburg, Russian Federation)
08:30P948Impact of left bundle branch block on left atrial dyssynchrony and its relationship to left ventricular diastolic function in dilated cardiomyopathySeong-Mi PARK (Seoul, Korea Republic of)
08:30P949Early circulating predictors of post-infarction myocardial remodeling pattern  
08:30P950Early left ventricular reverse remodelling after sacubitril/valsartan treatment in clinical practiceMario GALVAN RUIZ (Las Palmas De G. C., Spain)
08:30P952Dynamical 3D modeling possibilities in the left ventricle reconstructions Personalized surgical approach in cardiac surgery 
08:30P953Corrected QT interval and right shifted association with mortality in acute heart failure patientsHae-Young LEE (Seoul, Korea Republic of)
08:30P954Long term outcome and factors associated with reduced systolic ventricular function in survivors of sudden cardiac arrestHelle SOEHOLM (Copenhagen Nv, Denmark)
08:30P955Ivabradine in the treatment of heart failure with reduced ejection fractionGulnaz DADASHOVA (Baku, Azerbaijan)
08:30P956Endocrine hormonal imbalance in heart failure with reduced ejection fractionMatthias NAEGELE (Zurich, Switzerland)
08:30P957Reduction in the number of heart failure hospitalizations in patients included in a heart failure unit.Victor MARTINEZ DOSANTOS (Madrid, Spain)
08:30P958Predictors of recovery of left ventricular ejection fraction in patients included in a heart failure unitDiego IGLESIAS DEL VALLE (Madrid, Spain)
08:30P959Reduction of the need for diuretic treatment in patients included in a heart failure unit Victor MARTINEZ DOSANTOS (Madrid, Spain)
08:30P960Ejection fraction monitoring in patients with heart failure: the improved ejection fraction as a prognostic markerMaria Lorena CORONEL (Corrientes, Argentina)
08:30P961Efficacy of heart failure reversal treatment followed by 90 days follow up in chronic heart failure patients with low ejection fraction 
08:30P962The impact of coronary artery disease on clinical outcomes in heart failure with mid-range ejection fraction patientsJeong Cheon CHOE (Busan, Korea Republic of)
08:30P963The value of bioimpedance vector analysis in decompensated heart failure patients with mid-range ejection fractionAnna KLIMENKO (Moscow, Russian Federation)
08:30P964Left ventricular systolic dysfunction before planned surgical revascularization: "grey area" featuresOlga YEPANCHINTSEVA (Kyiv, Ukraine)
08:30P965Heart failure with mid-range ejection fraction: characteristics and outcome in patients with and without acute kidney injuryIoan Radu LALA (Arad, Romania)
08:30P966Mortality in patients with heart failure and midrange ejection fractionAntonio XAVIER FONTES (Vila Franca Do Campo, Portugal)
08:30P967Impact of hypoalbuminemia in heart failure with preserved ejection fraction: a future therapeutic target?Maria Ines PIRES (Viseu, Portugal)
08:30P968Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO-TTRThibaud DAMY (Creteil, France)
08:30P969Impact of gender on the association between diastolic function and left atrial strain in atrial fibrillation patients with preserved ejection fraction 
08:30P970Effect of inspiratory muscle training on functional capacity in patients with heart failure with preserved ejection fraction: does baseline inspiratory muscle function matters?Patricia PALAU SAMPIO (Valencia, Spain)
08:30P971Potential usefulness of diastolic stress-test echocardiography in patients with suspicion of heart failure with preserved ejection fraction - a pilot studyEvgeny BELYAVSKIY (Berlin, Germany)
08:30P972Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)Javed BUTLER (Atlanta, United States of America)
08:30P973Independent predictors of sudden cardiac death in patients with ischemic chronic heart failure with preserved ejection fraction and renal dysfunctionDmytro LASHKUL (Zaporizhzhya, Ukraine)
08:30P974Rationale, design and methodology of the APOLLON trial: A population-based, observational registry of heart failure with mid-range and preserved ejection fraction Murat BITEKER (Istanbul, Turkey)
08:30P975What influences exercise capacity in male and female with heart failure and preserved ejection fraction of left ventricle?Ekaterina CHERNYAEVA (Kiev, Ukraine)
08:30P976Norepinephrine, plasma renin activity and prognosis in chronic systolic heart failureAlberto AIMO (Pisa, Italy)
08:30P977Clinical outcome and prognosis in patient with acute heart failureAshok TAHILYANI (Singapore, Singapore)
08:30P978Difference in n-terminal pro-b-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF) and non-cardiac comorbidityEkaterina CHERNYAEVA (Kiev, Ukraine)